JPMorgan analyst Anupam Rama downgraded Camp4 Therapeutics (CAMP) to Neutral from Overweight without a price target The company’s private placement provides a cash runway into 2027, but this is balanced by its the lead program CMP-SYNGAP-01 for Syngap-related disorders being in the very early stage, the analyst tells investors in a research note. JPMorgan now sees a long time horizon to patient level value creation for the shares.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAMP:
- Camp4 Therapeutics price target lowered to $12 from $18 at Piper Sandler
- Biotech Alert: Searches spiking for these stocks today
- CAMP4 Therapeutics Secures $100M in Private Placement
- Camp4 Therapeutics announces oversubscribed private placement up to $100M
- Camp4 Therapeutics appoints Doug Williams as board chair, Dan Tardiff as CSO